Literature DB >> 29752854

Perioperative factors associated with persistent opioid use after extensive abdominal surgery in children and adolescents: A retrospective cohort study.

Pascal Owusu-Agyemang1,2, Juan P Cata1,2, Antoinette Van Meter1, Ravish Kapoor1, Acsa M Zavala1, Uduak U Williams1, January Tsai1, Elizabeth Rebello1, Lei Feng3, Andrea Hayes-Jordan4.   

Abstract

BACKGROUND: In adults, preoperative opioid use and higher perioperative opioid consumption have been associated with higher odds of persistent opioid use after surgery. There are limited data on the prevalence and factors associated with persistent opioid use after major oncologic surgery in children. AIMS: In this study, we sought to determine the prevalence and factors associated with the development of persistent opioid use in a group of children and adolescents who had undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
METHODS: A retrospective study of patients ≤19 years of age was performed. Univariable logistic regression was used to assess factors associated with a postdischarge persistent opioid use of up to 6 months.
RESULTS: Eighty-six children were identified. The median age was 12 years, and 43% were female. The proportion of patients with persistent opioid use over the immediate 3, 6, 12 and 24 postdischarge months was 54/77 (70%), 18/51 (35%), 13/45 (29%), and 3/24 (13%), respectively. The daily average in-patient pain scores were higher in the group of children who subsequently developed persistent opioid use of up to 6 months (estimated difference 0.5, 95% confidence interval [CI]: 0.3, 0.8, P < .01). Furthermore, higher postoperative opioid consumption was associated with greater odds of a subsequent persistent opioid use of up to 6 months (odds ratio 1.03, 95% CI: 1.00, 1.07, P = .05).
CONCLUSION: In this retrospective study of children and adolescents who had undergone a major oncologic surgery, higher in-patient pain scores and higher postoperative opioid consumption were associated with a persistent opioid use of up to 6 months.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  adolescents; children; oncology; opioids; pain

Mesh:

Substances:

Year:  2018        PMID: 29752854     DOI: 10.1111/pan.13386

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  5 in total

1.  Impact of Ketamine on Opioid Use and Persistent Pain After Cytoreductive Surgery with Hyperthermic Chemotherapy.

Authors:  Juan P Cata; Pascal Owusu-Agyemang; Dhanalakshmi Koyyalagunta; German Corrales; Lei Feng; Keith Fournier
Journal:  J Pain Res       Date:  2021-08-13       Impact factor: 3.133

2.  Assessment of Persistent and Prolonged Postoperative Opioid Use Among Patients Undergoing Plastic and Reconstructive Surgery.

Authors:  Cristen Olds; Emily Spataro; Kevin Li; Cherian Kandathil; Sam P Most
Journal:  JAMA Facial Plast Surg       Date:  2019-07-01       Impact factor: 4.611

3.  Acute postoperative opioid consumption trajectories and long-term outcomes in pediatric patients after spine surgery.

Authors:  Mandy Mj Li; Don Daniel Ocay; Alisson R Teles; Pablo M Ingelmo; Jean A Ouellet; M Gabrielle Pagé; Catherine E Ferland
Journal:  J Pain Res       Date:  2019-05-23       Impact factor: 3.133

4.  Predicting Acute Postoperative Pain Trajectories and Long-Term Outcomes of Adolescents after Spinal Fusion Surgery.

Authors:  Don Daniel Ocay; Mandy M J Li; Pablo Ingelmo; Jean A Ouellet; M Gabrielle Pagé; Catherine E Ferland
Journal:  Pain Res Manag       Date:  2020-02-24       Impact factor: 3.037

Review 5.  Guidelines for Opioid Prescribing in Children and Adolescents After Surgery: An Expert Panel Opinion.

Authors:  Lorraine I Kelley-Quon; Matthew G Kirkpatrick; Robert L Ricca; Robert Baird; Calista M Harbaugh; Ashley Brady; Paula Garrett; Hale Wills; Jonathan Argo; Karen A Diefenbach; Marion C W Henry; Juan E Sola; Elaa M Mahdi; Adam B Goldin; Shawn D St Peter; Cynthia D Downard; Kenneth S Azarow; Tracy Shields; Eugene Kim
Journal:  JAMA Surg       Date:  2021-01-01       Impact factor: 14.766

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.